Surrozen, Inc.

NASDAQ:SRZN

Biotechnology

Healthcare
$31.74 -4.74%

-$1.14 today

Market cap
$237.33M
Beta
0.51
P/E (TTM)
-0.7
EPS (TTM)
-$31.29
52W Low $8.00High $35.00

Volume 0.31M

Average 0.11M

SRZN Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Surrozen, Inc.NASDAQ: SRZN

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) growth accelerates

Q1 FY2026 weighted avg shares (diluted) of 10.95M shares rose 201.8% year over year, ahead of the +179.8% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 20.3% from the prior quarter. Over 3 fiscal years it compounded at +47.8% a year.

Context

  • Weighted avg shares (diluted) increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +201.8% holds above the trailing-twelve-month pace of +179.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
10.95M+20.3% QoQ
Last fiscal yearDec 2025
7.48M+155.0% YoY
LTMMar 2026
9.29M+179.8% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+201.8%——
1 year+155.0%——
3-year CAGR+47.8%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
7.48M USD
Year-over-year change
+155.0%
4-year CAGR
+33.8%

Weighted Avg Shares (Diluted) vs competitors

How SRZN compares with its peers on the latest reported figures

  • SRZN's LTM Mar 2026 weighted avg shares (diluted) of 9.29M shares is the 7th highest of the 8 companies compared; the peer median is 34.62M shares.
  • Its year-over-year change of +179.8% is the 2nd highest of 8, against a peer median of +19.9%.
  • Over three fiscal years its annual growth of +47.8% compares with a peer median of +28.3%.
SRZN Competitors Peer median
Weighted Avg Shares (Diluted) for SRZN and competitors
Company Period LTM YoY 3-year CAGR
IRDOpus Genetics, Inc.LTM Mar 2026406.29M +1283.9%+211.4%
CGTXCognition Therapeutics, Inc.LTM Mar 202679.93M +69.4%+35.9%
SEERSeer, Inc.LTM Mar 202656.96M -7.5%-2.7%
IMMXImmix Biopharma, Inc.LTM Mar 202634.62M +19.9%+33.4%
AGENAgenus Inc.LTM Mar 202633.65M +50.2%+28.3%
GLSIGreenwich LifeSciences, Inc.LTM Mar 202613.8M +5.4%+1.6%
SRZNSurrozen, Inc.LTM Mar 20269.29M +179.8%+47.8%
TILInstil Bio, Inc.LTM Mar 20266.73M +3.3%+1.0%
Peer median (excluding SRZN) 34.62M+19.9%+28.3%

Competitors are the stored peer set for SRZN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue012.5M010.66M3.48M
Cost of Revenue3.3M3.27M27.23M0537K
Gross Profit(3.3M)9.23M(27.23M)10.66M2.94M
Gross Margin—73.8%—100.0%84.6%
Research & Development36.88M37.01M27.23M21.13M29.37M
Selling, General & Admin14.21M19.83M15.8M15.06M16.2M
Operating Expenses51.09M53.57M18.55M36.19M45.03M
Depreciation & Amortization3.3M1.96M1.91M1.44M537K
EBITDA(51.35M)(34.05M)(41.13M)(62.12M)(241.49M)
EBITDA Margin—-272.4%—-583.0%-6945.3%
Operating Income(54.39M)(44.34M)(45.78M)(25.54M)(42.09M)
Operating Margin—-354.7%—-239.7%-1210.6%
Interest Income72K781K2.34M1.69M3.02M
Interest Expense00000
Other Income / Expenses(257K)8.34M2.74M(38.03M)(199.93M)
Income Before Tax(54.65M)(36M)(43.04M)(63.56M)(242.03M)
Pre-Tax Margin—-288.0%—-596.6%-6960.8%
Income Tax Expense00000
Net Income(52.51M)(36M)(43.04M)(63.56M)(242.03M)
Net Margin—-288.0%—-596.6%-6960.8%
EPS (Basic)(23.40)(15.55)(21.33)(21.67)(32.37)
EPS (Diluted)(23.40)(15.55)(21.33)(21.67)(32.37)
Weighted Avg Shares2.34M2.31M2.02M2.93M7.48M
Weighted Avg Shares (Diluted)2.34M2.31M2.02M2.93M7.48M

Surrozen, Inc.

NASDAQ:SRZN

Intrinsic Alpha fair value

Locked

Current Price

$31.74

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.